经审核，监事会认为：公司董事会编制和审核《2023 年半年度报告》及其 摘要的程序符合法律、行政法规、中国证监会的规定，报告内容真实、准确、完 整地反映了公司 2023 年半年度经营的实际情况，不存在任何虚假记载、误导性 陈述或者重大遗漏。 《2023 年半年度报告》及其摘要于同日发布于中国证监会指定的创业板上 市公司信息披露网站巨潮资讯网。 表决结果：3 票同意，0 票反对，0 票弃权，本议案获得通过。 证券代码：300194 证券简称：福安药业 公告编号：2023-052 福安药业（集团）股份有限公司 第五届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称 "公司"）第五届监事会第十 一次会议于 2023 年 8 月 29 日在公司会议室召开。应到监事 3 名，实到监事 3 名。会议通知已于 2023 年 8 月 19 日以电话、传真、邮件等方式发出。本次会 议的召集、召开与表决程序符合《公司法》、公司章程的规定。 本次会议由监事会主席杨勇先生主持，公司全体监事出席了会议。经与会监 事认 ...

非经营性资金占用 资金占用方 名称 占用方与上 市公司的关 联关系 上市公司 核算的会 计科目 2023 年期初 占用资金 余额 2023 年 1-6 月 占用累计发生 金额（不含利 息） 2023 年 1-6 月 占用资金的利 息（如有） 2023 年 1-6 月偿还累计 发生金额 2023 年期 末占用资金 余额 占用形成 原因 占用性质 控股股东、实际控制 人及其附属企业 无 不适用 不适用 不适用 不适用 小 计 —— —— —— —— —— 前控股股东、实际控 制人及其附属企业 无 不适用 不适用 不适用 不适用 小 计 —— —— —— —— —— 其他关联方及其附 属企业 无 不适用 不适用 不适用 不适用 小 计 —— —— —— —— —— 总 计 —— —— —— —— —— 其他关联资金往来 资金往来方 名称 往来方与上 市公司的关 联关系 上市公司 核算的会 计科目 2023 年 期初往来 资金余额 2023 年 1-6 月 往来累计发生 金额（不含利 息） 2023 年 1-6 月 往来资金的利 息（如有） 2023 年 1-6 月 偿还累计 发生金额 2023 年 期末往来 资金余 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 691,025,769.13, representing a year-over-year increase of 25.03% compared to CNY 552,693,027.82 in Q1 2022[5] - Net profit attributable to shareholders for Q1 2023 was CNY 86,023,255.31, a significant increase of 130.86% from CNY 37,261,834.25 in the same period last year[5] - The net profit after deducting non-recurring gains and losses was CNY 75,396,700.92, up 141.06% from CNY 31,277,517.05 in Q1 2022[5] - Basic earnings per share for Q1 2023 were CNY 0.07, reflecting a 133.33% increase from CNY 0.03 in Q1 2022[5] - Total operating revenue for Q1 2023 reached ¥691,025,769.13, an increase of 25.1% compared to ¥552,693,027.82 in the same period last year[24] - Net profit for Q1 2023 was ¥88,250,623.91, significantly higher than ¥37,369,678.01 in Q1 2022, marking an increase of 136%[24] - The net profit attributable to the parent company for Q1 2023 was ¥86,023,255.31, a significant increase of 130.7% compared to ¥37,261,834.25 in the same period last year[26] - The total comprehensive income for Q1 2023 reached ¥89,861,967.18, up from ¥35,001,141.95 in Q1 2022, reflecting a growth of 156.5%[26] - The basic and diluted earnings per share for Q1 2023 were both ¥0.07, compared to ¥0.03 in Q1 2022, indicating a 133.3% increase[26] Cash Flow - The company's cash flow from operating activities showed a net outflow of CNY 67,428,674.56, a decline of 215.68% compared to a net inflow of CNY 58,291,240.96 in the previous year[15] - Cash inflows from operating activities totaled ¥630,138,811.39, an increase from ¥581,681,774.88 in the previous year, representing an 8.3% growth[29] - The net cash flow from operating activities was negative at -¥67,428,674.56, contrasting with a positive net cash flow of ¥58,291,240.96 in the same period last year[29] - Cash flow from financing activities for Q1 2023 was CNY 422,211,794.20, a substantial increase of 435.23% compared to a net outflow of CNY 125,945,830.64 in the same period last year[15] - The company raised ¥503,080,000.00 through financing activities in Q1 2023, compared to only ¥88,000,000.00 in the same period last year, indicating a substantial increase of 471.5%[29] - The net cash flow from financing activities was positive at ¥422,211,794.20, a significant turnaround from a negative cash flow of -¥125,945,830.64 in Q1 2022[29] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 6,295,381,169.09, an increase of 7.10% from CNY 5,877,980,374.42 at the end of the previous year[5] - Current assets totaled ¥2,331,885,668.81, up from ¥1,927,072,477.67, indicating a rise of 21%[22] - The company's total liabilities increased to ¥2,258,053,259.87 from ¥1,931,511,616.76, reflecting a growth of 16.9%[22] - The total equity attributable to shareholders reached ¥4,033,721,243.87, up from ¥3,945,089,460.91, an increase of 2.2%[22] - The total amount of cash and cash equivalents decreased from 1,010,326,594.35 CNY at the beginning of the year to 688,531,150.99 CNY at the end of the period[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 43,952[17] - The largest shareholder, Wang Tianxiang, holds 24.00% of the shares, totaling 285,499,420 shares[17] - The company has a total of 214,124,565 shares under lock-up for the largest shareholder, Wang Tianxiang, due to executive lock-up restrictions[19] - The second-largest shareholder, Jiang Chen, holds 2.53% of the shares, totaling 30,062,100 shares[17] - The total number of restricted shares decreased from 223,588,823 to 221,835,508 during the reporting period[19] Expenses and Costs - Total operating costs for Q1 2023 were ¥613,468,747.82, up from ¥530,171,239.60, reflecting a rise of 15.7%[24] - The company reported a significant increase in financial expenses, which rose by 103.30% due to higher interest payments on bank loans[13] - Research and development expenses for Q1 2023 were ¥27,929,150.50, slightly higher than ¥26,813,029.82 in the previous year[24] Market and Future Outlook - The increase in revenue was primarily driven by higher sales volumes of certain products and an increased proportion of products won in national procurement, leading to a decrease in sales expenses as a percentage of revenue[9] - The company has no new product or technology developments mentioned in the reports[18] - There are no significant market expansion or acquisition strategies disclosed in the reports[18] - The company has not provided specific future outlook or performance guidance in the available documents[18] - The company reported a significant decrease in contract liabilities from ¥61,840,402.32 to ¥32,691,760.53, a reduction of 47.3%[22] - The company did not report any net profit from subsidiaries prior to consolidation in Q1 2023, consistent with the previous year[26]

证券代码： 300194 证券简称：福安药业 福安药业(集团)股份有限公司投资者关系活动记录表 编号：2023-001 | 投资者关系活 | □特定对象调研 □ 分析师会议 | | --- | --- | | 动类别 | □ 媒体采访 √ 业绩说明会 | | | □ 新闻发布会 □ 路演活动 | | | 现场参观 □ | | | 其他 （请文字说明其他活动内容） □ | | 参与单位名称 | 投资者网上提问 | | 及人员姓名 | | | 时间 | 2023 年 4 月 7 日 (周五) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待 | 1、董秘汤沁 | | 人员姓名 | 2、财务负责人余雪松 | | | 3、董事长汪天祥 | | | 4、独立董事陈耿 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、请问懂事长，股价反应企业现状，长期在 4 元上下意味着 | | | 是否与企业现状匹配。 | ...

Financial Performance - The company's operating revenue for 2022 was ¥2,421,742,292.37, a decrease of 1.28% compared to ¥2,453,144,920.88 in 2021[25]. - The net profit attributable to shareholders for 2022 was ¥204,607,567.44, representing a significant increase of 168.91% from a loss of ¥296,913,080.60 in 2021[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥161,266,687.31, up 149.86% from a loss of ¥323,433,987.92 in 2021[25]. - The net cash flow from operating activities increased by 32.03% to ¥339,498,850.22 in 2022, compared to ¥257,128,839.71 in 2021[25]. - The total assets at the end of 2022 were ¥5,877,980,374.42, an increase of 3.01% from ¥5,706,459,375.59 at the end of 2021[25]. - The net assets attributable to shareholders increased by 5.65% to ¥3,945,089,460.91 at the end of 2022, compared to ¥3,734,107,363.48 at the end of 2021[25]. - The company reported a basic earnings per share of ¥0.17 for 2022, compared to a loss of ¥0.25 in 2021, marking a 168.00% improvement[25]. - The weighted average return on equity for 2022 was 5.33%, a recovery from -7.58% in 2021[25]. - The company achieved operating revenue of 2.422 billion yuan in 2022, remaining stable compared to the previous year[60]. - The net profit attributable to shareholders was 205 million yuan, marking a turnaround from a loss, with profit levels slightly increasing compared to the previous year[60]. Research and Development - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[20]. - The company is focusing on enhancing its R&D capabilities to adapt to the evolving pharmaceutical landscape and capitalize on opportunities arising from industry consolidation[35][36]. - The company has 58 drug research and development projects currently in the registration process, indicating a strong pipeline for future products[50]. - The company emphasizes a research and development strategy that combines independent innovation with collaborative efforts, ensuring a continuous and forward-looking R&D process[50]. - The company has made significant progress in product research and development, with multiple drugs approved for production, including acetylcysteine inhalation solution and sodium valproate injection[61][62]. - The company is actively pursuing new product registrations, with 12 drugs currently under review, which could significantly impact future sales[54]. - The company is committed to maintaining high standards in drug development and regulatory compliance, which is crucial for sustaining competitive advantage[56]. - The company has established a comprehensive sales system and network, optimizing market promotion strategies to enhance sales capabilities[62]. - The company maintains a strong focus on R&D as a core competitive advantage, with a well-structured and experienced research team[58]. Risk Management - The company emphasizes the importance of risk awareness regarding future plans and performance forecasts, highlighting potential operational risks[6]. - The company has established a comprehensive risk management framework to address various operational challenges[6]. - The company emphasizes strict compliance with safety, environmental, and quality regulations to mitigate operational risks[115]. Corporate Governance - The company has committed to ensuring the accuracy and completeness of its financial reports, with key personnel affirming the integrity of the annual report[5]. - The company maintains a commitment to corporate governance and social responsibility, aligning its operations with industry standards[20]. - The company has a complete and independent financial management system, including separate bank accounts and tax obligations[125]. - The company has a diverse board with members holding various professional backgrounds, enhancing governance[133]. - The company has engaged in providing guarantees for subsidiaries to secure bank credit facilities, indicating a proactive approach to financial management[140]. - The company emphasizes the protection of shareholder rights and adheres to relevant laws and regulations to ensure fair information disclosure[174]. Environmental Compliance - The company has implemented environmental protection measures, including the construction of specialized facilities to reduce pollutant emissions and prevent major environmental accidents[163]. - The company reported a total discharge of COD at 15.0 tons, with ammonia nitrogen at 0.245 tons, indicating compliance with the discharge standards[165]. - The company maintained pH levels between 6 and 9, with ammonia nitrogen ≤ 45 mg/l and chemical oxygen demand ≤ 500 mg/l, adhering to the wastewater discharge standards[166]. - The company has established a comprehensive monitoring system to ensure all discharge parameters remain within the legal limits[166]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[173]. Employee and Management - The total number of employees at the end of the reporting period is 3,229, with 3,179 from major subsidiaries and 50 from the parent company[148]. - The company has a total of 1,340 production personnel, 388 sales personnel, and 996 technical personnel among its workforce[148]. - The company emphasizes talent development through various training programs to enhance employee skills and capabilities[150]. - The management team includes experienced professionals with backgrounds in various pharmaceutical sectors, enhancing the company's operational capabilities[135]. - The company has established a comprehensive salary mechanism that links compensation to performance and responsibilities[149]. Strategic Initiatives - The company is actively pursuing strategic partnerships and potential acquisitions to bolster its market position[20]. - The company anticipates challenges from industry policies and competition, particularly in the areas of drug pricing and market expansion[111]. - The company will strengthen talent recruitment and training to improve the professional and management capabilities of its workforce[110]. - The company will continue to optimize its product structure and increase market maintenance efforts to enhance core competitiveness[112].

证券代码：300194 证券简称：福安药业 公告编号：2023-024 福安药业（集团）股份有限公司 关于举行2022年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称"公司"）《2022 年年度报告》已 于 2023 年 3 月 31 日公告于中国证监会指定信息披露网站巨潮资讯网。为进一 步解读公司年度报告，帮助广大投资者更深入全面地了解公司经营情况，公司定 于 2023 年 4 月 7 日（星期五）下午 15:00-17:00 在全景网提供的网上平台举行 2022 年度网上业绩说明会。本次说明会将采用网络远程方式举行，投资者可登 陆投资者互动平台"全景·路演天下"（http://rs.p5w.net ）参与本次业绩说明 会。 出席本次年度业绩说明会的人员有：公司董事长兼总经理汪天祥、财务总监 余雪松、董事会秘书汤沁、独立董事陈耿。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会 提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 7 ...

福安药业（集团）股份有限公司 2022 年第三季度报告 证券代码：300194 证券简称：福安药业 公告编号：2022-059 福安药业（集团）股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 福安药业（集团）股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | 项目 | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末比 | | --- | --- | --- | --- | --- | | | | 期增减 | | 上年同期增减 | | 营业收入（元） | 633,391,050.74 | 4 ...

福安药业（集团）股份有限公司 2022 年半年度报告全文 福安药业（集团）股份有限公司 2022 年半年度报告 2022 年 8 月 1 福安药业（集团）股份有限公司 2022 年半年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 公司负责人汪天祥、主管会计工作负责人余雪松及会计机构负责人(会计主管人员)甘小丽声明：保证本半 年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 对半年度报告涉及未来计划等前瞻性陈述的风险提示 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成公司对任何投资者及相关人士的承 诺，投资者及相关人士均应对此保持足够的风险认识，并且应当理解计划、预测与承诺之间的差异。 本公司请投资者认真阅读本半年度报告全文，并特别注意下列风险因素： 公司已在本报告中详细阐述公司在生产经营过程中可能面临的各种风险及应对措施，请查阅"第三节、 管理层讨论与分析"之"十、公司可能面临的风险及应对措施"。敬请投资者予以关注，注 ...

[I. Main Financial Data](index=1&type=section&id=I.%20Main%20Financial%20Data) The company experienced a significant year-over-year decline in Q1 2022 performance, with revenue down 14.88% and net profit attributable to shareholders decreasing by 39.44%, while operating cash flow improved significantly Key Financial Indicators for Q1 2022 | Indicator | Current Period (CNY) | Prior Year Period (CNY) | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 552.69 million | 649.32 million | -14.88% | | Net Profit Attributable to Shareholders | 37.26 million | 61.53 million | -39.44% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) | 31.28 million | 54.84 million | -42.97% | | Net Cash Flow from Operating Activities | 58.29 million | -11.86 million | 591.52% | | Basic Earnings Per Share (CNY/share) | 0.03 | 0.05 | -40.00% | | Total Assets | 5.59 billion | 5.71 billion (Year-end prior period) | -2.04% (vs. year-beginning) | | Total Equity Attributable to Shareholders | 3.77 billion | 3.73 billion (Year-end prior period) | 0.97% (vs. year-beginning) | - Total non-recurring gains and losses for the current period amounted to **5.98 million CNY**, primarily comprising **8.82 million CNY** in government subsidies[5](index=5&type=chunk) Changes and Reasons for Key Accounting Data and Financial Indicators | Item | Change Rate | Primary Reason | | :--- | :--- | :--- | | **Balance Sheet Items** | | | | Long-term Deferred Expenses | 149.75% | Increase in factory renovation expenses during the period | | Salaries Payable | -69.43% | Issuance of year-end bonuses accrued in the prior period | | **Income Statement Items** | | | | Non-operating Income | 394.10% | Increase in government subsidies and compensation received during the period | | Income Tax Expense | -82.41% | Decrease in total profit during the period | | **Cash Flow Statement Items** | | | | Net Cash Flow from Operating Activities | 591.52% | Decrease in other related operating expenses paid | | Net Cash Flow from Financing Activities | -212.15% | Decrease in borrowings obtained during the period | [II. Shareholder Information](index=3&type=section&id=II.%20Shareholder%20Information) As of the reporting period end, the company had 50,121 common shareholders, with a relatively concentrated equity structure where controlling shareholder Wang Tianxiang held 24.00% - As of the end of the reporting period, the company had **50,121** common shareholders[14](index=14&type=chunk) Top 10 Shareholders' Holdings | Shareholder Name | Shareholder Type | Holding Percentage | Number of Shares Held | | :--- | :--- | :--- | :--- | | Wang Tianxiang | Domestic Natural Person | 24.00% | 285,499,420 | | Jiang Chen | Domestic Natural Person | 2.53% | 30,062,100 | | Fuan Pharmaceutical (Group) Co., Ltd. - Phase I Employee Stock Ownership Plan | Other | 1.75% | 20,862,213 | | Beijing Guoxing Property Management Co., Ltd. | Domestic Non-State-Owned Legal Person | 1.16% | 13,760,000 | | Sun Guanghui | Domestic Natural Person | 0.94% | 11,155,918 | | Huang Tao | Domestic Natural Person | 0.93% | 11,123,442 | | GRACEPEAK PTE LTD. | Overseas Legal Person | 0.87% | 10,346,937 | | Wang Yong | Domestic Natural Person | 0.50% | 5,943,635 | | Chen Zhiying | Domestic Natural Person | 0.47% | 5,550,000 | | Chen Zhizhan | Domestic Natural Person | 0.47% | 5,539,909 | - During the reporting period, the total number of restricted shares changed minimally from **246,583,172** shares at the beginning of the period to **246,483,942** shares at the end, primarily due to executive lock-up[16](index=16&type=chunk)[17](index=17&type=chunk) [III. Other Significant Matters](index=5&type=section&id=III.%20Other%20Significant%20Matters) The company's net profit declined 39.44% due to pandemic-affected sales, increased expenses, and lower associate income, while a US subsidiary's share repurchase agreement default poses a significant litigation risk - The company's net profit attributable to shareholders decreased by **39.44%** year-over-year, primarily due to: - Sales business impacted by the pandemic, leading to a **14.88%** year-over-year decrease in operating revenue - Management expenses and R&D expenses increasing by **13.80 million CNY** and **3.28 million CNY**, respectively - Underperformance of associates compared to the prior period, resulting in a **4.81 million CNY** decrease in investment income[18](index=18&type=chunk) - The company's subsidiary, Fuan Tianheng (USA) LLC, experienced a default on a Share Repurchase Agreement with a related party, as the repurchasing party failed to fully pay the first installment. The company has engaged lawyers to prepare for litigation, but as of April 25, 2022, the case has not yet been filed due to its cross-border nature[19](index=19&type=chunk)[20](index=20&type=chunk) [IV. Quarterly Financial Statements](index=6&type=section&id=IV.%20Quarterly%20Financial%20Statements) This section provides the unaudited consolidated financial statements for Q1 2022, including the balance sheet, income statement, and cash flow statement, reflecting the company's financial position and performance [1. Consolidated Balance Sheet](index=6&type=section&id=1.%20Consolidated%20Balance%20Sheet) As of March 31, 2022, total assets were **5.59 billion CNY** (down 2.04%), total liabilities **1.69 billion CNY** (down 8.27%), and equity attributable to owners of the parent **3.77 billion CNY** (up 0.97%) Key Items from Consolidated Balance Sheet | Item | Period-End Balance (CNY) | Year-Beginning Balance (CNY) | Change from Year-Beginning | | :--- | :--- | :--- | :--- | | Total Assets | 5.59 billion | 5.71 billion | -2.04% | | Total Liabilities | 1.69 billion | 1.84 billion | -8.27% | | Total Equity Attributable to Owners of Parent Company | 3.77 billion | 3.73 billion | 0.97% | | Total Equity | 3.90 billion | 3.87 billion | 0.93% | [2. Consolidated Income Statement](index=8&type=section&id=2.%20Consolidated%20Income%20Statement) In Q1 2022, total operating revenue was **552.69 million CNY** (down 14.88%), total operating costs **530.17 million CNY** (down 12.13%), and net profit attributable to owners of the parent **37.26 million CNY** (down 39.44%) Key Items from Consolidated Income Statement | Item | Current Period (CNY) | Prior Period (CNY) | YoY Change | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 552.69 million | 649.32 million | -14.88% | | Total Operating Costs | 530.17 million | 603.40 million | -12.13% | | Operating Profit | 39.43 million | 68.69 million | -42.60% | | Total Profit | 38.84 million | 68.08 million | -42.95% | | Net Profit | 37.37 million | 59.73 million | -37.43% | | Net Profit Attributable to Owners of Parent Company | 37.26 million | 61.53 million | -39.44% | [3. Consolidated Cash Flow Statement](index=10&type=section&id=3.%20Consolidated%20Cash%20Flow%20Statement) Net cash flow from operating activities significantly improved to **58.29 million CNY** (up 591.52%), while investing and financing activities resulted in net outflows, leading to a period-end cash balance of **770.31 million CNY** Key Items from Consolidated Cash Flow Statement | Item | Current Period (CNY) | Prior Period (CNY) | YoY Change | | :--- | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 58.29 million | -11.86 million | 591.52% | | Net Cash Flow from Investing Activities | -85.21 million | -114.52 million | Not Applicable | | Net Cash Flow from Financing Activities | -125.95 million | 112.30 million | -212.15% | | Net Increase in Cash and Cash Equivalents | -153.01 million | -14.54 million | Not Applicable | | Cash and Cash Equivalents at Period-End | 770.31 million | 791.65 million | -2.70% |

福安药业（集团）股份有限公司 2021 年年度报告全文 福安药业（集团）股份有限公司 2021 年年度报告 2022 年 04 月 1 福安药业（集团）股份有限公司 2021 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整，不存在虚假记载、误导性陈 述或者重大遗漏，并承担个别和连带的法律责任。 公司负责人汪天祥、主管会计工作负责人余雪松及会计机构负责人(会计主管人员)甘小丽声明：保证本年度报告中财务 报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司 2021 年度实现归属于上市公司股东的净利润为-2.97 亿元，同比下降 241.81%。 （一）业绩亏损原因 本报告期，归属于上市公司股东的净利润出现亏损，主要是本报告期：（1）Red Realty LLC 交易对方未按照回购协 议支付款项，且其未来持续经营存在不确定性，诉讼尚无实质进展，计提美国项目资产减值 6.23 亿；（2）只楚药业主要产 品销量、价格下降，出现减值迹象，计提只楚药业商誉减值准备 2.01 亿元。 （二）公司本报告期虽然亏损，但扣除以上资 ...